Jefferies analyst Brian Tanquilut reiterated a Buy rating and $200.00 price target on Amedisys (NASDAQ: AMED) after hosting management for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE